Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 22;27(16):5335.
doi: 10.3390/molecules27165335.

Promising Antimycobacterial Activities of Flavonoids against Mycobacterium sp. Drug Targets: A Comprehensive Review

Ali A Rabaan  1   2   3 , Saad Alhumaid  4 , Hawra Albayat  5 , Mohammed Alsaeed  6 , Fadwa S Alofi  7 , Mawaheb H Al-Howaidi  8 , Safaa A Turkistani  9 , Salah M Alhajri  10 , Hejji E Alahmed  11 , Abdulwahab B Alzahrani  12 , Mutaib M Mashraqi  13 , Sara Alwarthan  14 , Mashael Alhajri  14 , Fatimah S Alshahrani  15   16 , Souad A Almuthree  17 , Roua A Alsubki  18 , Abdulmonem A Abuzaid  19 , Mubarak Alfaresi  20   21 , Mona A Al Fares  22 , Abbas Al Mutair  23   24   25   26
Affiliations
Review

Promising Antimycobacterial Activities of Flavonoids against Mycobacterium sp. Drug Targets: A Comprehensive Review

Ali A Rabaan et al. Molecules. .

Abstract

Tuberculosis (TB) caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb) remains a threat to mankind, with over a billion of deaths in the last two centuries. Recent advancements in science have contributed to an understanding of Mtb pathogenesis and developed effective control tools, including effective drugs to control the global pandemic. However, the emergence of drug resistant Mtb strains has seriously affected the TB eradication program around the world. There is, therefore, an urgent need to develop new drugs for TB treatment, which has grown researchers' interest in small molecule-based drug designing and development. The small molecules-based treatments hold significant potential to overcome drug resistance and even provide opportunities for multimodal therapy. In this context, various natural and synthetic flavonoids were reported for the effective treatment of TB. In this review, we have summarized the recent advancement in the understanding of Mtb pathogenesis and the importance of both natural and synthetic flavonoids against Mtb infection studied using in vitro and in silico methods. We have also included flavonoids that are able to inhibit the growth of non-tubercular mycobacterial organisms. Hence, understanding the therapeutic properties of flavonoids can be useful for the future treatment of TB.

Keywords: Mycobacterium tuberculosis; anti-tubercular compounds; drug discovery; flavonoids.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pathogenesis of Mycobacterium tuberculosis.
Figure 2
Figure 2
Flavonoid classification with its structure.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Chakaya J., Khan M., Ntoumi F., Aklillu E., Fatima R., Mwaba P., Kapata N., Mfinanga S., Hasnain S.E., Katoto P.D. Global Tuberculosis Report 2020–Reflections on the Global TB Burden, Treatment and Prevention Efforts. Int. J. Infect. Dis. 2021;113:S7–S12. doi: 10.1016/j.ijid.2021.02.107. - DOI - PMC - PubMed
    1. Jeremiah C., Petersen E., Nantanda R., Mungai B.N., Migliori G.B., Amanullah F., Lungu P., Ntoumi F., Kumarasamy N., Maeurer M., et al. The WHO Global Tuberculosis 2021 Report–Not So Good News and Turning the Tide Back to End TB. Int. J. Infect. Dis. 2022. in press . - DOI - PMC - PubMed
    1. Ong C.W.M., Goletti D. Impact of the global COVID-19 outbreak on the Management of Other Communicable Diseases. Int. J. Tuberc. Lung Dis. 2020;24:547–548. doi: 10.5588/ijtld.20.0140. - DOI - PubMed
    1. Fedrizzi T., Meehan C., Grottola A., Giacobazzi E., Serpini G.F., Tagliazucchi S., Fabio A., Bettua C., Bertorelli R., De Sanctis V., et al. Genomic characterization of Nontuberculous Mycobacteria. Sci. Rep. 2017;7:45258. doi: 10.1038/srep45258. - DOI - PMC - PubMed
    1. Brites D., Gagneux S. Old and New Selective Pressures on Mycobacterium Tuberculosis. Infect. Genet. Evol. 2012;12:678–685. doi: 10.1016/j.meegid.2011.08.010. - DOI - PMC - PubMed

MeSH terms

Grants and funding

This research received no external funding.